|
1
|
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.
|
N Engl J Med
|
2009
|
4.45
|
|
2
|
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
|
J Clin Oncol
|
2010
|
2.49
|
|
3
|
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
|
J Clin Oncol
|
2013
|
2.15
|
|
4
|
Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks.
|
J Clin Oncol
|
2007
|
1.98
|
|
5
|
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
|
J Natl Cancer Inst
|
2011
|
1.94
|
|
6
|
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
|
Blood
|
2011
|
1.93
|
|
7
|
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
|
J Clin Oncol
|
2009
|
1.80
|
|
8
|
Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5.
|
J Clin Oncol
|
2006
|
1.68
|
|
9
|
Distinctive pulmonary histopathology with increased IgG4-positive plasma cells in patients with autoimmune pancreatitis: report of 6 and 12 cases with similar histopathology.
|
Am J Surg Pathol
|
2009
|
1.68
|
|
10
|
Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes.
|
Qual Life Res
|
2010
|
1.61
|
|
11
|
Quality of life after breast cancer surgery: What have we learned and where should we go next?
|
J Surg Oncol
|
2009
|
1.60
|
|
12
|
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
|
J Clin Oncol
|
2012
|
1.58
|
|
13
|
Depressive symptoms in healthy apolipoprotein E ε4 carriers and noncarriers: a longitudinal study.
|
J Clin Psychiatry
|
2013
|
1.41
|
|
14
|
Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
|
Neuro Oncol
|
2012
|
1.37
|
|
15
|
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
|
Breast Cancer Res Treat
|
2013
|
1.34
|
|
16
|
Transoral laser microsurgery followed by radiation therapy for oropharyngeal tumors: the Mayo Clinic Arizona experience.
|
Head Neck
|
2013
|
1.26
|
|
17
|
Triple-negative breast cancers: unique clinical presentations and outcomes.
|
Ann Surg Oncol
|
2010
|
1.21
|
|
18
|
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment.
|
Support Care Cancer
|
2013
|
1.21
|
|
19
|
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
|
J Clin Oncol
|
2011
|
1.21
|
|
20
|
Increase in contralateral prophylactic mastectomy: echoes of a bygone era? Surgical trends for unilateral breast cancer.
|
Ann Surg Oncol
|
2010
|
1.20
|
|
21
|
Pretransplant risk score for new-onset diabetes after kidney transplantation.
|
Diabetes Care
|
2011
|
1.13
|
|
22
|
Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force.
|
Cancer
|
2012
|
1.08
|
|
23
|
Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.
|
Breast Cancer Res Treat
|
2014
|
1.08
|
|
24
|
Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.
|
Ann Surg Oncol
|
2013
|
1.07
|
|
25
|
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
|
Cancer
|
2013
|
1.06
|
|
26
|
Malignant melanoma in the elderly: different regional disease and poorer prognosis.
|
J Cancer
|
2011
|
1.06
|
|
27
|
Analysis and interpretation of results based on patient-reported outcomes.
|
Value Health
|
2007
|
1.04
|
|
28
|
The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes.
|
Twin Res Hum Genet
|
2009
|
1.03
|
|
29
|
Longitudinal modeling of cognitive aging and the TOMM40 effect.
|
Alzheimers Dement
|
2012
|
1.01
|
|
30
|
Effects of carpal tunnel syndrome on adaptation of multi-digit forces to object weight for whole-hand manipulation.
|
PLoS One
|
2011
|
1.00
|
|
31
|
The impact of obesity on breast cancer: a retrospective review.
|
Ann Surg Oncol
|
2012
|
0.97
|
|
32
|
Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities.
|
Radiat Oncol
|
2011
|
0.97
|
|
33
|
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.
|
Clin Cancer Res
|
2011
|
0.95
|
|
34
|
The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials.
|
J Cancer
|
2012
|
0.94
|
|
35
|
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.
|
Oncologist
|
2011
|
0.94
|
|
36
|
Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look?
|
Ann Surg Oncol
|
2010
|
0.92
|
|
37
|
Cancer with diabetes: prevalence, metabolic control, and survival in an academic oncology practice.
|
Endocr Pract
|
2012
|
0.87
|
|
38
|
Risk factors associated with local and in-transit recurrence of cutaneous melanoma.
|
Am J Surg
|
2010
|
0.87
|
|
39
|
Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
|
Biol Blood Marrow Transplant
|
2013
|
0.86
|
|
40
|
Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.
|
Br J Haematol
|
2015
|
0.85
|
|
41
|
A significant number of women present with palpable breast cancer even with a normal mammogram within 1 year.
|
Am J Surg
|
2010
|
0.85
|
|
42
|
The Mayo Clinic manuscript series relative to the discussion, dissemination, and operationalization of the Food and Drug Administration guidance on patient-reported outcomes.
|
Value Health
|
2007
|
0.85
|
|
43
|
Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform.
|
BMC Med Genomics
|
2010
|
0.84
|
|
44
|
Effects of carpal tunnel syndrome on adaptation of multi-digit forces to object mass distribution for whole-hand manipulation.
|
J Neuroeng Rehabil
|
2012
|
0.84
|
|
45
|
Anxiety affects cognition differently in healthy apolipoprotein E ε4 homozygotes and non-carriers.
|
J Neuropsychiatry Clin Neurosci
|
2011
|
0.83
|
|
46
|
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.83
|
|
47
|
Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.
|
Cancer
|
2013
|
0.82
|
|
48
|
North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.
|
Clin Breast Cancer
|
2012
|
0.82
|
|
49
|
Effects of carpal tunnel syndrome on dexterous manipulation are grip type-dependent.
|
PLoS One
|
2013
|
0.81
|
|
50
|
Does magnetic resonance imaging accurately predict residual disease in breast cancer?
|
Am J Surg
|
2009
|
0.80
|
|
51
|
Scientific Presentation Award: The impact of magnetic resonance imaging on surgical treatment of invasive breast cancer.
|
Am J Surg
|
2009
|
0.79
|
|
52
|
Preoperative predictors of nipple-areola complex involvement for patients undergoing mastectomy for breast cancer.
|
Ann Surg Oncol
|
2011
|
0.78
|
|
53
|
Laparoscopic radical nephrectomy for very large renal tumors (> or =10 cm): is there a size limit?
|
J Endourol
|
2009
|
0.77
|
|
54
|
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.
|
Support Care Cancer
|
2009
|
0.76
|
|
55
|
Predictive testing for Alzheimer's disease: suicidal ideation in healthy participants.
|
Alzheimer Dis Assoc Disord
|
2015
|
0.76
|
|
56
|
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.
|
Bone
|
2010
|
0.75
|
|
57
|
APOE varepsilon2 and presymptomatic stage Alzheimer disease: how much is not enough?
|
Neurology
|
2010
|
0.75
|
|
58
|
Determination of mild, moderate, and severe pain interference in patients with cancer.
|
Pain
|
2017
|
0.75
|
|
59
|
Risk Factors Predicting Positive Margins at Primary Wide Local Excision of Cutaneous Melanoma.
|
Dermatol Surg
|
2016
|
0.75
|
|
60
|
The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma.
|
Am J Surg
|
2011
|
0.75
|